Gujar SA - Search Results

1

Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.

Clements DR, Sterea AM, Kim Y, Helson E, Dean CA, Nunokawa A, Coyle KM, Sharif T, Marcato P, Gujar SA, Lee PW. Clements DR, et al. Among authors: gujar sa. J Immunol. 2015 May 1;194(9):4397-412. doi: 10.4049/jimmunol.1402132. Epub 2015 Mar 30. J Immunol. 2015. PMID: 25825443

2

Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity.

Gujar SA, Marcato P, Pan D, Lee PW. Gujar SA, et al. Mol Cancer Ther. 2010 Nov;9(11):2924-33. doi: 10.1158/1535-7163.MCT-10-0590. Epub 2010 Oct 26. Mol Cancer Ther. 2010. PMID: 20978162

3

Oncolytic virus-initiated protective immunity against prostate cancer.

Gujar SA, Pan DA, Marcato P, Garant KA, Lee PW. Gujar SA, et al. Mol Ther. 2011 Apr;19(4):797-804. doi: 10.1038/mt.2010.297. Epub 2011 Jan 18. Mol Ther. 2011. PMID: 21245852 Free PMC article.

4

Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.

Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW. Marcato P, et al. Stem Cells. 2011 Jan;29(1):32-45. doi: 10.1002/stem.563. Stem Cells. 2011. PMID: 21280157

5

Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Shmulevitz M, Gujar SA, Ahn DG, Mohamed A, Lee PW. Shmulevitz M, et al. Among authors: gujar sa. J Virol. 2012 Jul;86(13):7403-13. doi: 10.1128/JVI.00304-12. Epub 2012 Apr 24. J Virol. 2012. PMID: 22532697 Free PMC article.

6

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.

Gujar S, Dielschneider R, Clements D, Helson E, Shmulevitz M, Marcato P, Pan D, Pan LZ, Ahn DG, Alawadhi A, Lee PW. Gujar S, et al. Mol Ther. 2013 Feb;21(2):338-47. doi: 10.1038/mt.2012.228. Epub 2012 Nov 13. Mol Ther. 2013. PMID: 23299799 Free PMC article.

7

Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis.

Pan D, Marcato P, Ahn DG, Gujar S, Pan LZ, Shmulevitz M, Lee PW. Pan D, et al. PLoS One. 2013;8(1):e54006. doi: 10.1371/journal.pone.0054006. Epub 2013 Jan 16. PLoS One. 2013. PMID: 23342061 Free PMC article.

8

Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.

Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PW. Hill R, et al. Among authors: gujar sa. Cell Death Dis. 2013 Sep 5;4(9):e791. doi: 10.1038/cddis.2013.307. Cell Death Dis. 2013. PMID: 24008735 Free PMC article.

9

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.

Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW. Gujar SA, et al. Br J Cancer. 2014 Jan 7;110(1):83-93. doi: 10.1038/bjc.2013.695. Epub 2013 Nov 26. Br J Cancer. 2014. PMID: 24281006 Free PMC article.

10

The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Pan LZ, Ahn DG, Sharif T, Clements D, Gujar SA, Lee PW. Pan LZ, et al. Among authors: gujar sa. Cell Cycle. 2014;13(6):1041-8. doi: 10.4161/cc.28128. Epub 2014 Feb 7. Cell Cycle. 2014. PMID: 24552824 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters